This study evaluates the biodistribution and tumor-targeting efficacy of 89Zirconium-labeled CI-8993, a monoclonal antibody against V-domain Ig suppressor of T-cell activation (VISTA), using positron emission tomography (PET) imaging. The research aims to visualize and quantify VISTA expression in vivo, providing insights into the potential of CI-8993 as an immunotherapeutic agent.
PET imaging revealed specific accumulation of 89Zr-labeled CI-8993 in VISTA-expressing tissues and tumors, indicating effective targeting. The study demonstrates the feasibility of using radiolabeled CI-8993 for non-invasive imaging of VISTA expression, supporting its potential utility in patient stratification and monitoring responses to VISTA-targeted therapies.
The study utilized a humanized VISTA Knockin mouse model developed in collaboration with genOway. This model expresses human VISTA in place of the murine counterpart, allowing for the assessment of human-specific antibody interactions and the evaluation of CI-8993's targeting capabilities in a physiologically relevant setting.
Immuno-oncology, Immune checkpoint inhibition, Molecular imaging, Monoclonal antibody therapy, Tumor immunology
Humanized Knockin model, Radiolabeling, PET imaging, In vivo antibody distribution, Immune checkpoint targeting
From model design to experimental results
Featured in 600+ scientific articles
Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions
Generated with biopharma partners and in-house
and guaranteed freedom to operate
Models with certified health status from professional breeders in US and Europe
